Mesenchymal stromal cell products

What MSC products are

Mesenchymal stromal cells, also called mesenchymal stem cells (MSCs), may be sourced from adult tissues such as bone marrow or adipose tissue; FDA's cell-therapy guidance expressly includes mesenchymal and adipose sources in its adult stem-cell category.^[S4] A product is characterized by more than a short surface-marker panel. Source tissue, donor, culture history, identity, viability, differentiation state, secreted factors, extracellular vesicles, and functional activity can all be relevant to defining the lot. The attributes selected for testing should follow the proposed mechanism and intended route of administration.

US regulatory status

Ryoncil (remestemcel-L-rknd)

FDA approved Ryoncil (remestemcel-L-rknd) on December 19, 2024. It is indicated for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older.^[S1] FDA's current cellular and gene therapy product list includes Ryoncil and does not list another MSC product.^[S2] This is a narrower US indication than the Japanese product described in the source text, and no claim about clinical performance is made here.

Development questions

Mechanism and potency strategy

An MSC program may propose secreted factors, extracellular vesicles, cell contact, or differentiation as contributors to activity. Translate that hypothesis into a potency strategy that links a defined product attribute to a functional assay. If more than one mechanism is proposed, decide whether a matrix of assays is needed and identify which assay is suitable for lot release. Do not assume that identity markers alone establish potency or predict a patient outcome.

Distribution after systemic administration

For an intravenously administered product, measure early lung signal, subsequent clearance, distribution to other organs, and persistence at the intended site. For a locally administered product, evaluate retention, migration, and unintended distribution. The sampling schedule and assay sensitivity should be adequate to distinguish a short-lived signal from persistent cells. These measurements establish biodistribution in the selected model; they do not predict clinical homing.

Donor, tissue source, passage, and alloimmune response

Design comparability studies to separate donor effects, tissue-source effects, passage number, culture scale, and cryopreservation. Measure identity, viability, growth, senescence-related attributes, HLA phenotype, and the chosen potency readout using lots that span the proposed manufacturing range. For an allogeneic product, include assays that can detect recipient immune recognition under conditions relevant to the intended dosing schedule.

A product-specific nonclinical program

1. Potency assays tied to the proposed mechanism

Choose functional readouts from the proposed mechanism and intended indication. Depending on that hypothesis, the panel might measure T-cell proliferation, macrophage phenotype, endothelial-cell responses, or specified secreted factors. Define reference material, system suitability, variability, and acceptance criteria before using an assay for release or comparability. A composite index is useful only when each component and its decision rule are justified.

2. Cell tracking and biodistribution

A biodistribution plan can pair longitudinal imaging, such as BLI or PET when technically justified, with tissue-specific quantitation by ddPCR or qPCR. Use orthogonal methods to address distribution, clearance, persistence, and unintended accumulation after the intended route of administration. Explain label stability, assay specificity for human cells, limits of detection, and how tissue collection times were chosen. The data compare routes or formulations within the model; they do not validate a strategy for avoiding pulmonary entrapment in patients.

3. Mechanistic studies in disease-relevant systems

Use a disease-relevant system to test a prespecified mechanistic hypothesis, such as whether an inflammatory environment changes the product's phenotype or secretory profile. Single-cell RNA sequencing and extracellular-vesicle analysis can characterize interactions among administered MSCs, immune cells, and resident cells. Such exploratory data may support biomarker selection or refine a potency hypothesis, but they do not establish clinical efficacy.

4. Alloimmune response, tumorigenicity, and ectopic tissue

For an allogeneic product, consider mixed-lymphocyte assays, anti-HLA antibody measurements, and repeat-exposure designs when they address the intended dosing regimen. Long-term studies may need to examine persistence, proliferation, tumor formation, and ectopic tissue at sites identified by biodistribution. FDA places MSCs within its product-specific cell-therapy framework, which calls for test-system and study-duration choices based on the product's biology.^[S4] These data characterize nonclinical hazards; they do not establish a clinical safety window.

Questions for a testing laboratory

Ask whether one laboratory can test the final manufactured lot across potency, post-thaw handling, biodistribution, immune-response, and pathology endpoints, or whether samples and methods must transfer between sites. Require a clear account of model limitations, assay validation, sample traceability, and comparability after process changes. MSC products are handled by FDA CBER under the cell-therapy framework and licensed through a Biologics License Application.^[S3][S4] Laboratory selection does not determine clinical success.